REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1522945
Clinical and Basic Research Advances on Jinlong Capsule for the Prevention and Treatment of Liver Cancer
Provisionally accepted
- 1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, Beijing Municipality, China
- 2Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 3Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Primary liver cancer, characterized by an insidious onset, rapid progression, high degree of heterogeneity, difficulties in treatment, and a short survival time, poses a significant threat to human health. Jinlong capsule (JLC), an original drug developed in China, is a Chinese patent medicine used to treat liver cancer. Research has demonstrated the antitumor effects of JLC, attributed to its unique preparation process. When used in combination with modern treatment methods, JLC helps in preventing and treating liver cancer recurrence and metastasis, prolonging patient survival, increasing the tumor objective response rate, alleviating gastrointestinal adverse reactions, enhancing survival quality, regulating immune functions of the body, relieving clinical symptoms, and improving patient safety. This study provides a review of clinical and basic research results on JLC. Methods: We performed literature searches in the Cochrane Library, Embase, PubMed, OVID Scopus, China Biology Medicine, China National Knowledge Infrastructure, VIP, and Wanfang databases for articles published from database inception to December 2023. Results: Basic research has revealed that the effects of JLC include the inhibition of tumor growth in vivo and in vitro and immune modulation. The possible mechanisms include inhibiting tumor cell proliferation, promoting tumor cell apoptosis, inhibiting angiogenesis, and modulating cellular immunity. Discussion: By attuning to the complex biological characteristics of liver cancer, harnessing the unique and unconventional advantages of traditional Chinese medicine, and focusing on clinical needs, we propose directions for future evidence-based research on using JLC in the prevention and treatment of liver cancer. This will contribute to the development of precision synergistic strategies that combine traditional Chinese medicine and modern medicine treatment methods.
Keywords: primary liver cancer, Jinlong capsule, evidence-based research, precision synergistic strategy, Prospective research
Received: 05 Nov 2024; Accepted: 19 May 2025.
Copyright: © 2025 Lv, Ren, Zhang, Lin and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jie Liu, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.